Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 12 Dual GIPGLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential Authors Bastin M , Andreelli F Received 12 May 2019 Accepted for publication 17 August 2019 Published 30 September 2019 Volume 2019:12 Pages 19731985 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Konstantinos Tziomalos Marie Bastin, Fabrizio Andreelli Diabetology-Metabolism Department, Sorbonne Universit, ICAN, Assistance Publique Hpitaux de Paris, Piti-Salptrire Hospital, Paris, F-75013, France Correspondence: Fabrizio Andreelli Diabetology-Metabolism Department, Piti-Salptrire Hospital, 47-83 Boulevard de lHpital, Paris cedex 13, 75951, France Email [email protected] Abstract: The need for efficient and safe therapy to improve such metabolic diseases as obesity and type 2 diabetes mellitus is currently unmet
Our preclinical findings demonstrate promising efficacy, with FASN inhibition significantly ameliorating diabetes-induced liver injury in a rodent experimental model. This provides further evidence for the weight-independent metabolic effects of semaglutide in managing MASH
Phospholipid abnormalities in early Alzheimer's disease Arch Neurol 1995
Phase 3 studies examining semaglutide specifically for NASH are ongoing
Neuroscience 149 , 822833 (2007)
